Biodex

Other

Centre National De La Recherche Scientifique

Huels Aktiengesellschaft

Commissariat a L'energie Atomique

Vestolit Gmbh

Marcel Jozefowicz

Veronique Migonney

Peter Ottersbach

Jean-Pierre Vairon

Jacqueline Jozefonvicz

Frank F Hill

Graciella Djavid

Didier Letourneur

Colette Douzon

Daniel A Muller

José Correia

Robert D Rosenberg

Christine Anders

Axel Stieneker

Laurent Sedel

Thomas Neu

Hervé Petite

Frederic Chaubet

Heinz Hermann Meyer

Britta Mensing

Christine Fougnot

Jose Correia

By Friedrich Frank Hill

By Regina Luise Hill

Remi Huynh

Latifa Dahri

Frédéric Chaubet

Alain Meunier

Delphine Logeart-Avramoglou

Cinderella Blanchat

Rémi Huynh

Latifa Dahricorreia

Latifa Dahri-Correia

The invention concerns pharmaceutical compositions with wound healing or anti-complementary activity, and their uses, said compositions comprising, (1) at least a dextran derivative of general formula DMCBSu, a, b, and c respectively representing the degrees of substitution in the groups MC, B and Su, wherein a&#x2267;0.6, b=0 or &#x2267;0.1, and c=0 or ranges widely between 0.1 and 0.5 for a wound healing composition, and a&#x2267;0.3, b&#x2267;0.1 and c=0 or ranges widely between 0.1 and 0.4 for a composition with anti-complementary activity; (2) and at least a pharmaceutically acceptable carrier, said dextran derivative being present in a single unit dose or at a concentration adapted to the desired wound healing or anti-complementary activity.

Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative

The invention concerns a biologically active material essentially comprising at least an insolubilized dextran derivative of general formula DMCBSUSand at least a growth factor having an activity on osteoarticular, dental and/or maxillofacial tissues, and the method for preparing same. The invention also concerns the uses of said biomaterial for preparing a repair or filing material, such as an implant, for osteoarticular, dental or maxillofacial applications and for preparing an orthopaedic, dental or maxillofacial prosthesis, and the prosthesis coated with said biologically active material.

Biomaterial based on an insolubilized dextran derivative and a growth factor

The invention concerns dextran derivatives, their applications as medicines with specific biological action, and their preparation method. Said derivatives correspond to the general formula DMC B SU S , in which: D represents a polysaccharide chain, preferably consisting of sequences of glucoside units, MC represents methylcarboxylate groups, B represents carboxymethylbenzylamide groups, Su represents sulphate groups, S represents sulphonate groups, a, b, c and d represent the degree of substitution (ds), respectively in groups, MC, B, Su and S; a being equal to 0 or &gE;0.3, b being equal to 0 or &gE;0.1, c being equal to 0 or &gE;0.1 and d being equal to 0 or &gE;0.1 provided that when d&equals;0, a and/or b are not equal to 0, said products having homogeneity of chain size distribution, illustrated by a gauss elution profile symmetrical in high performance steric exclusion chromatography, and homogeneity in the distribution of charged chemical groups, illustrated by an elution profile with a single symmetrical peak in low pressure ion-exchange chromatography.

Dextran derivatives, preparation and medicinal applications

The invention relates to water-insoluble polymers which promote cell proliferation, contain carboxylate and sulfonate groups and are obtainable by free radical copolymerization of one or more aliphatically unsaturated monomers containing carboxylate groups, or the correspondingly functionalized derivatives of the monomers, as component I with one or more aliphatically unsaturated monomers containing sulfonate groups, or the correspondingly functionalized derivatives of the monomers, as component II and a component III which comprises an aliphatically unsaturated monomer or several aliphatically unsaturated monomers, the correspondingly functionalized derivatives being converted into carboxylate and sulfonate groups after the copolymerization, and to a process for their preparation, wherein the polymers are useful for forming articles which promote cell proliferation.

Carboxylate-sulfonate polymers

Preparation of carboxylate-sulfonate polymers having cell proliferation-promoting properties

Bioactive surface coating

The invention relates to water-insoluble, bacteriophobic and optionally cell proliferation-inhibiting polymers obtainable by free-radical polymerization of (a) at least one monomer of the general formula R&mdash;(A),, in which R is an aliphatically unsaturated organic radical with the valence a, A is a carboxyl group &mdash;COOH, sulfuric acid group &mdash;OSO,OH, sulfonic acid group &mdash;SO,H, phosphoric acid group &mdash;OPO(OH),, phosphonic acid group &mdash;PO(OH),, phosphorous acid group &mdash;OP(OH),, a phenolic hydroxyl group or a salt of one of the groups, and a is 1, 2 or 3, with the proviso that, if the monomer of the formula I contains a carboxyl group &mdash;COOH or a carboxylate group, either this monomer contains at least one further radical A having a different one of the definitions specified for A, or at least one further monomer of the formula I is also used in which A has a different one of the definitions specified for A; and (b) at least one other aliphatically unsaturated monomer, wherein the polymers are useful for forming bacteriophobic or cell proliferation-inhibiting articles.

Water insoluble bacteriophobic polymers containing carboxyl and sulfonic acid groups

A process for preparing molding materials having anticoagulant properties is described. Hydrophobic monomers are subjected to free-radical copolymerization with hydrophilic monomers having biospecifically active functions to produce the molding material. The molding material may then be shaped into articles which also have anticoagulant properties. These articles are extremely useful in, for example, medical applications in contact with a patient's biological fluid.

Molding materials having anticoagulant properties, their preparation and

These resins derived from a crosslinked styrene (co)-polymer, or from a crosslinked dextran, comprise a (co)-polymer chain which is substituted with one or more groups, which may be identical or different, belonging to the following categories: --Z--A.sub.1 ; --Z--A.sub.2 ; --Z--A.sub.1 --Z'--A.sub.2 ; --Z--A.sub.1 --A.sub.3 --A.sub.2 ; --Z--A.sub.1 --A.sub.4, where Z=spacer chain, Z'=linking chain, A.sub.1 =phosphate residue, A.sub.2 =residue of purine or pyrimidine base, A.sub.3 =sugar residue and A.sub.4 =residue of a molecule participating in the polar structure of various phospholipids. These resins are applicable for the analysis and purification of molecules of biological origin, in particular as a stationary phase in ion-exchange and affinity chromatography, especially for carrying out the fractionation of protein mixtures. Their interaction with proteins, in particular the anti-DNA and anti-phospholipid antibodies present in the serum of patients suffering from SLE, makes them applicable to operations for the selective purification of the different types of antibodies developed by Lupus patients.

Polymers derived from crosslinked polystyrenes and dextrans, their

These resins derived from a crosslinked styrene (co)-polymer, or from a crosslinked dextran, comprise a (co)-polymer chain which is substituted with one or more groups, which may be identical or different, belonging to the following categories: --Z--A.sub.1 ; --Z--A.sub.2 ; --Z--A.sub.1 --Z'--A.sub.2 ; --Z--A.sub.1 --A.sub.3 --A.sub.2 ; --Z--A.sub.1 --A.sub.4, where Z=spacer chain, Z'=linking chain, A.sub.1 =phosphate residue, A.sub.2 =residue of purine or pyrimidine base, A.sub.3 =sugar residue and A.sub.4 =residue of a molecule participating in the polar structure of various phospholipids. These resins are applicable for the analysis and purification of molecules of biological origin, in particular as a stationary phase in ion-exchange and affinity chromatography, especially for carrying out the fractionation of protein mixtures. Their interaction with proteins, in particular the anti-DNA and anti-phospholipid antibodies present in the serum of patients suffering from SLE, makes them applicable to operations for the selective purification of the different types of antibodies developed by lupus patients.

The present invention relates to a process for separating and purifying proteases and antiproteases. This process is characterized in that there are placed in contact an insoluble cross-linked polymer including in its chain the group --SO.sub.3 R.sub.1 -- and/or the group --SO.sub.2 R.sub.2 -- in which R.sub.1 denotes a hydrogen atom or metal and R.sub.2 denotes the remainder of an amino acid linked to the --SO.sub.2 -- bridge through its amine --NH--, function, with the solution containing proteases and antiproteases or their complex; separating the polymer which has absorbed the desired protein, washing it carefully with the buffer, desorbing the absorbed protein by a solution of a polycationic compound in the case of T or by an albumin solution in the case of AT or of the complex T-AT, and isolating the protein, if desired, by known means, such as, especially, freeze drying. The invention is useful for studying the mechanism of blood coagulation.

Process for the separation and purification of proteases and

Growing community of inventors

Lamorlaye, France

Marcel Jozefowicz